Study of ARO-MAPT-SC in Healthy Participants and Participants With Early Alzheimer's Disease

Abroad (travel likely)RecruitingPHASE1, PHASE2

Conditions

Alzheimer Disease · Alzheimer Disease, Early Onset

Simple summaryAI-assisted

This summary is produced by a language model and is experimental. It may be incomplete or inaccurate and is not a substitute for professional medical advice.

Locations

Research Site 3, East York, Ontario, Canada
Research Site 2, Toronto, Ontario, Canada
Research Site 1, Grafton, Auckland, New Zealand

View source on ClinicalTrials.gov

Similar trials

Other trials that are currently recruiting and may be relevant based on condition, treatment, phase, or location

Study to Evaluate the Efficacy, Safety, and Tolerability of BMS-986368, for the Treatment of Agitation in Participants With Alzheimer's Disease

Agitation · Alzheimer Disease

Abroad (travel likely)RecruitingPHASE2

Homewood, United States · Huntsville, United States

A Study of Donanemab (LY3002813) in Participants Who Completed Study AACM (TRAILBLAZER-ALZ 3-EXT).

Alzheimer Disease · Dementia · Plaque, Amyloid

Abroad (travel likely)RecruitingPHASE3

Phoenix, United States · Huntington Beach, United States

A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of DNL628 in Participants With Early Alzheimer's Disease

Alzheimer Disease, Early Onset

Abroad (travel likely)RecruitingPHASE1

's-Hertogenbosch, Netherlands · Amsterdam, Netherlands

Fisetin in Mild Alzheimer's Disease

Alzheimer s Disease · Alzheimer Dementia · Alzheimer Dementia (AD)

Abroad (travel likely)RecruitingPHASE2

Toronto, Canada